Skip to main content
. 2018 Dec 13;7(1):e00450. doi: 10.1002/prp2.450

Figure 2.

Figure 2

DS‐5272 ameliorates Cisplatin nephropathy. Rats were injected with cisplatin (5 mg/kg) with or without MDM2 inhibitor DS‐5272 (10 mg/kg) (cisplatin (−)/DS‐5272 (−), n = 4; cisplatin (−)/DS‐5272 (+), n = 5; cisplatin (+)/DS‐5272 (−), n = 5; cisplatin (+)/DS‐5272 (+), n = 5). (A) Serum creatinine levels were determined on Days 1, 3, 5 and 10. *P < 0.05 cisplatin (+)/DS‐5272 (−) vs cisplatin (+)/DS‐5272 (+). (B) KIM‐1 expression was determined by western blotting on Day 3. (C) Tubular injuries were visualized by periodic acid‐Schiff (PAS) staining on Day 3 and (D) tubular injury scores were quantified on Days 3 and 5 and plotted. *P < 0.05 cisplatin (+)/DS‐5272 (−) vs cisplatin (+)/DS‐5272 (+). (E) Tubular cell death was analyzed by TUNEL staining on Day 3. (F) TUNEL‐positive cells were quantified on Days 3 and 5 and plotted. *P < 0.05 cisplatin (+)/DS‐5272 (−) vs cisplatin (+)/DS‐5272 (+). All images shown are representative of at least 10 determinations